
1023

RAW SEQUENCE LISTING ERROR REPORT BEST AVAILABLE COPY

of tittern &



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number:	09/888,/82
Source:	0186
Date Processed by STIC:	11/1/2001

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,

2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216. PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax) PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE <u>CHECKER</u> <u>VERSION 3.0 PROGRAM</u>, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW:

Checker Version 3.0

The Checker Version 3.0 application is a state-of the-art Windows based software program employing a logical and intuitive user-interface to check whether a sequence listing is in compliance with format and content rules. Checker Version 3.0 works for sequence listings generated for the original version of 37 CFR §§1.821 – 1.825 effective October 1, 1990 (old rules) and the revised version (new rules) effective July 1, 1998 as well as World Intellectual Property Organization (WIPO) Standard ST.25.

Checker Version 3.0 replaces the previous DOS-based version of Checker, and is Y2K-compliant. Checker allows public users to check sequence listings in Computer Readable form (CRF) before submitting them to the United States Patent and Trademark Office (USPTO). Use of Checker prior to filing the sequence listing is expected to result in fewer errored sequence listings, thus saving time and money.

Checker Version 3.0 can be down loaded from the USPTO website at the following address: http://www.uspto.gov/web/offices/pac/checker

OIPE

RAW SEQUENCE LISTING

DATE: 11/01/2001

PATENT APPLICATION: US/09/888,182

TIME: 14:15:17

Input Set : A:\ES.txt

Output Set: N:\CRF3\11012001\I888182.raw

Does Not Comply Corrected Diskette Needed

ERRORED SEQUENCES

-> 2 <210> SEQ ID NO: 1

3 <211> LENGTH: 27

4 <212> TYPE: DNA

5 <213> ORGANISM: Artificial Sequence

W--> 6 <220> FEATURE:

7 <223> OTHER INFORMATION: Description of Artificial Sequence: Erk5-specific

primer 8

W--> 0 <110> APPLICANT:

W--> 0 <120> TITLE INVENTION:

W--> 0 <160> NUMBER OF SEQ ID NOS:

W--> 9 <400> SEQUENCE: 1

E--> 10 cagccattcg atgtgggccc acgcta

26

Ill following pages

Pleese consult Sequera Rules

for wabit formet.

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/888,182

DATE: 11/01/2001

TIME: 14:15:18

Input Set : A:\ES.txt

Output Set: N:\CRF3\11012001\1888182.raw

```
L:2 M:283 W: Missing Blank Line separator, <210> field identifier
L:6 M:283 W: Missing Blank Line separator, <220> field identifier
L:0 M:282 W: Numeric Field Identifier Missing, <110> is required.
L:0 M:282 W: Numeric Field Identifier Missing, <120> is required.
L:0 M:282 W: Numeric Field Identifier Missing, <160> is required.
L:9 M:283 W: Missing Blank Line separator, <400> field identifier
L:10 M:252 E: No. of Seq. differs, <211>LENGTH:Input:27 Found:26 SEQ:1
L:16 M:283 W: Missing Blank Line separator, <220> field identifier
L:19 M:283 W: Missing Blank Line separator, <400> field identifier
L:26 M:283 W: Missing Blank Line separator, <220> field identifier
L:30 M:283 W: Missing Blank Line separator, <400> field identifier
L:31 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:37 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:41 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:42 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:43 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:44 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:50 M:283 W: Missing Blank Line separator, <220> field identifier
L:54 M:283 W: Missing Blank Line separator, <220> field identifier
L:58 M:283 W: Missing Blank Line separator, <400> field identifier
L:59 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4
L:60 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4
L:61 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4 L:62 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4
L:65 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4
L:78 M:283 W: Missing Blank Line separator, <220> field identifier
L:82 M:283 W: Missing Blank Line separator, <400> field identifier
L:83 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5
L:85 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5
L:88 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5
L:99 M:283 W: Missing Blank Line separator, <220> field identifier
L:106 M:283 W: Missing Blank Line separator, <400> field identifier
L:107 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:108 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:109 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:110 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:111 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:112 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:113 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:0 M:203 E: No. of Seq. differs, <160> Number Of Sequences: Input (0) Counted (6)
```

2/107
2/207
2/407
2/407
2/407
2/407
2/407
2/407
2/407
2/407
2/407
2/407
2/407
2/407
2/407
2/407
2/407
2/407
2/407
2/407
2/407
2/407
2/407
2/407
2/407
2/407
2/407
2/407
2/407
2/407
2/407
2/407
2/400>
1
cagccattcg atgtgggccc acgcta
2/400>
2/400>
2/400>
2/400>
2/400>
2/400>
2/400>

Del ret page for more enon

<210> 3
<211> 802
<212> DNA
<213> Mus musculus
<220>
<221> misc_feature
<222> (1)..(38)
<223> partial sequence of exon 2 from Erk5 gene
<400> 3
cgcnacctac tgtgccctat ggaggaattc agatctgtg aagggagtgg gccaggagga 60
ggagacacag tcgggatcag cttagaagcc caggttcagt aatactgaag ttctggcagg 120
gcggttgaac ccagagtgat gcgggctgtg agtccaggac attggtaggg acagttctta 180

(partial listing of Seg. 3)

Use of n and/or Xaa has been detected in the Sequence Listing. Review the Sequence Listing to insure a corresponding explanation is presented in the <220> to <223> fields of each sequence using n or Xaa.

more n's are shown in seg. 3

sel sample Sequence Listing (attached)

```
Smith, John: Smithgene Inc.
             <110>
             <120>
                          Example of a Sequence Listing
(not mandator 130>
                          01-00001
                                                                                             ويبين
                          PCT/EP98/00001
            <140>
                          1998-12-31
            <1(1>
            <150>
                          US 08/999,999
            <151>
                          1997-10-15
            <160>
            <170>
                          PatentIn version 2.0
            <210>
                         389
            <211>
                         ANG
            <212>
                         Paramecium sp.
            <213>
            <220>
                         CDS
            <221>
            <222>
                         (279) ... (389)
           <300>
            <301>
                         Doc. Richard
                         Isolation and Characterization of a Gene Encoding a
            <302>
                         Protease from Paramecium sp.
            <303>
                         Journal of Genes
           < 304 >
            <305>
            <306>
                         1 - 7
            <307>
                         1988-06-31
           <308>
                         123456
           <309>
                         1988-06-31
           <400>
                                                                                                    60
                                                                 caccctgcta
                                                                              atcagatete
           agciglagic
                         attcctgtgt<sup>h</sup>
                                      cctcttctct
                                                    criggictics
                                                                                                   120
                                                    tgcagottca
                                                                 caggcaggca
                                                                              ggcaggcagc
           agggagagtg
                         tcttgaccc.t;
                                      cctctgcctt
                                                                                                   180
                                                                              tgggttccgc
           cgatgtggca
                         attgctggca
                                      gtgccacagg
                                                    cttttcagcc
                                                                 aggettaggg
                                                                                                   240
                                                                              cctctcgctc
           cgcggcgcgg
                         cggcccctct
                                      cgcgctcctc
                                                   tcgcgcctct
                                                                 ctctcgctct
```

1

Appendix 3, page 2

,	att aggtga	gcag gagg	aggggg	cagttag	c	atg Met 1	gtt Val	tca Ser	atg Met	ttc Phe 5	agc Ser	296
ttg tc Leu Sc		tgg cct Trp Pro	gga Gly	ttt tgt Phe Cys 15	ttg Leu	ttt Phe	gtt Val	tgt Cys	t t g Leu 20	ttc Phe	caa Cln	344
tgt cc Cys Pre		ctc ccc Leu Pro	tgt Cys	cac tca His Ser 30	tca Ser	ctg -Leu	cag Gln			ctt "bė u"	.	389
<210>	2			:	<i>t</i> ~					i y cr	-	
<211> <212> <213>	37 PRT Paramed	ium sp.				Part Saget	*i	, 	•			
<<00> Het Val	2 Ser Met	Phe Ser	Leu	Ser Phe	Lys 10	Trp	Pro	Gly	Phg	Cys 15	Leu	
Phe Val	Cys Leu 20	Phe Cln	Cys	Pro Lys 25	Val	Leu	Pro	Cys	His 30	Ser	Ser	
Leu Gln	Pro Asn 35	Lgu							:			
<210> <211> <212> <213>	} 11 PRT Artific	 ial Sequen	ce		ż			-		. `		
<220> <223>	Designe Linker l	d peptide between the	based o	n siże an and beta	d pola chair	rity s of	to ac Prote	tasa in XY	n Z .			
<400> Net Val	} Asn Leu	Glu Pro S	Met I	His Thr	Glu 10	He						
<210><400>	4 4											

[Annex VIII follows]

E

table. The numeric identifier shall be used only in the "Sequence Listing." The order and presentation of the items of information in the "Sequence Listing" shall conform to the arrangement given below. Each item of information shall begin on a new line and shall begin with the numeric identifier enclosed in angle brackets as shown. The submission of those items of information designated with an "M" is mandatory. The submission of those items of information designated with an "O" is optional. Numeric identifiers <110> through <170> shall only be set forth at the beginning of the "Sequence Listing." The following table illustrates the numeric identifiers.

Numeric Identifier	Definition	Comments and Format	Mandatory (M) or Optional (O)
<110>	Applicant	Preferably max. of 10 names; one name per line; preferable format: Surname, Other: Names and/or Initials	M v
<120>	Title of Invention		M
<130>	File Reference	Personal file reference	M when filed prior to assignment of appl. number
<140>	Current Applica- tion Numbér	Specify as: US 07/999,999 or PCT/US96/99999	M, if available
<141>	Current Filing Date	Specify as: yyyy-mm-dd	M, if available
<150>	Prior Application Number	Specify as: US 07/999,999 or PCT/US96/99999	M, if applicable include priority documents under 35 USC 119 and 120
<151>	Prior Application Filing Date	Specify as: yyyy-mm-dd	M, if applicable
<160>	Number of SEQ ID NOs	Count includes total number of SEQ ID NOs	М
<170>	Software / /	Name of software used to create the Sequence Listing	0 =
<210>	SEQ ID NO: #:	Response shall be an integer representing the SEQ ID NO shown	М
<211>	Length	Respond with an integer expressing the number of bases or amino acid residues	M

.<212>

Type

Whether presented sequence moleculc is DNA, RNA, or PRT (protein). If a nucleotide sequence contains both DNA and RNA fragments, the type shall be "DNA." In addition, the combined DNA/ RNA molecule shall be further described in the <220> to <223> feature section.

<213>

Organism.

Scientific name, i.e. Genus/species, Unknown or Artificial Sequence. In addition, the "Unknown" or "Artificial Sequence" organisms shall be further described in the <220> to <223> feature section.

<220>

Feature

4

Leave blank after <220>. <221-223> provide for a description of points of biological significance in the sequence.

M, under the following conditions: if "n,"
"Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGAN-ISM is "Artificial Sequence" or "Unknown"; if molecule is combined DNA/RNA.

М

<221>

Name/Key

Provide appropriate identifier for feature, pre-ferably from WIPO Standard ST.25 (1998), Appendix 2, Tables 5 and 6

M, under the following conditions:= if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence

<222>

Location

Specify location within sequence; where appropriate state number of first and last bases/amino acids

M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified

base was used in

a sequence

<223>	Other Information	Other relevant information; four lines maximum	ORGÁNISM is "Artificial
			Sequence" or
	e®e °	. -	"Unknown"; if 🛥 🕳
:	*		molecule is com-
	·		bined DNA/RNA.
< 20.05	Publication	Leave blank	0
<300>	Information	after <300> /* **	15.7.2
	111101111111111111111111111111111111111	order (300)	
<301>	Authors	Preferably max	0
		of ten named	•
	•	authors of publi-	
		cation; specify	
	·	one name per line;	
		preferable format: Surname, Other	<i>:</i>
		Names and/or	
		Initials	•
	•		
<302>	Title		O :
. 2.0.2			0
<303>	Journal		0
<304>	Volume		0
13017	vorame	<i>,</i>	
<305>	Issue		0
<306>	Pages		0 ·
<307>	Date	Journal date on which data published; specify as yyyy-mm-dd, MMM-yyyy or	0
	•	Season-yyyy	•
< 308 >	Database	Accession number	0 .
(300)	Accession	assigned by data-	· ·
	Number	base including	
		database name	□
			.
<309>	Database Entry	Date of entry in	0
	Date (database; specify as yyyy-mm-dd or	
		MMM-yyyy	•
	•		
<310>	Patent Document	Document number:	0
	Number	for patent-type	
		citations only.	
	• .	Specify as, for	
	•	example, US 07/999,999	
			_

in feature

·<311>	Patent Filing Date	Document filing date, for patent-type citations only; specify as yyyy-mm-dd	•
<312>	Publication Date	Document publication date, for patent-type citations only; specify as yyyy-mm-dd	O .
<313>	Relevant Residues	FROM (position) TO (position)	0
<400>	Sequence	follow the numeric identifier and should appear on the line pre-	M → E

- 5. Section 1.824 is revised to read as follows:
- 1.824 Form and format for nucleotide and/or amino acid sequence submissions in computer readable form.
- (a) The computer readable form required by 1.021(e) shall meet the following specifications:
- (1) The computer readable form shall contain a single "Sequence Listing" as either a diskette, series of diskettes, or other permissible media: outlined in paragraph (c) of this section.
- (2) The "Sequence Listing" in paragraph (a) (1) of this section shall be submitted in American Standard Code for Information Interchange (ASCII) text. No other formats shall be allowed.
- (3) The computer readable form may be created by any means, such as word processors, nucleotide/amino acid sequence editors or other custom computer programs; however, it shall conform to all specifications detailed in this section.
- (4) File compression is acceptable when using diskette media, so long as the compressed file is in a self-extracting format that will decompress on one of the systems described in paragraph (b) of this section.
- (5) Page numbering shall not appear within the computer readable form version of the "Sequence Listing" file.
- (6) All computer readable forms shall have a label permanently affixed thereto on which has been hand-printed or typed: the name of the applicant, the title of the invention, the date on which the data were recorded on the computer readable form, the operating system used, a reference number, and an application serial number and filing date, if known.
- (b) Computer readable form submissions must meet these format requirements:
- (1) Computer: IBM PC/XT/AT, or compatibles, or Apple Macintosh;
- (2) Operating System: MS-DOS, Unix or Macintosh;